Coenen V A, Gielen F L H, Castro-Prado F, Abdel Rahman A, Honey C R
Surgical Center for Movement Disorders, Division of Neurosurgery, University of British Columbia, Vancouver, Canada.
Acta Neurochir (Wien). 2008 Aug;150(8):757-62; discussion 762. doi: 10.1007/s00701-008-1619-5. Epub 2008 Jun 23.
Reversible changes in subthalamic nucleus (STN) activity, detected by microelectrode recording (MER), are reported in three patients who received an intravenous betablocker, metoprolol, during deep brain stimulation (DBS) for Parkinson's disease (PD).
Metoprolol (MP) was given intravenously to reduce blood pressure during surgery. Systolic blood pressure dropped by 4, 11 and 17%, indicating a systemic beta - adrenoceptor blocking effect.
In all patients, the bursting spiking activity of the STN was temporarily suppressed, after the application of MP. Unexpectedly, a transient reduction in Parkinson symptoms (rigidity) was recorded during suppression of STN spiking activity in patient 2.
The reversible suppression of STN activity and Parkinson symptoms with the beta1-selective adrenoceptor antagonist MP has not been reported. It supports the theory, that--as recently reported in the rat--the human STN is influenced by adrenergic inputs. This report supports the possible application of adrenergic antagonist drugs for the use in Parkinson's disease and advocates additional neurophysiological and pharmacological research in this field.
在三名帕金森病(PD)患者接受深部脑刺激(DBS)治疗期间静脉注射β受体阻滞剂美托洛尔时,通过微电极记录(MER)检测到丘脑底核(STN)活动出现可逆性变化。
手术期间静脉注射美托洛尔(MP)以降低血压。收缩压分别下降了4%、11%和17%,表明存在全身β-肾上腺素能受体阻断作用。
在所有患者中,应用MP后,STN的爆发性尖峰活动暂时受到抑制。出乎意料的是,在患者2的STN尖峰活动受到抑制期间,记录到帕金森症状(僵硬)出现短暂减轻。
尚未有关于β1选择性肾上腺素能受体拮抗剂MP对STN活动和帕金森症状产生可逆性抑制作用的报道。这支持了如下理论,即正如最近在大鼠中所报道的那样,人类STN受肾上腺素能输入的影响。本报告支持肾上腺素能拮抗剂药物在帕金森病治疗中的可能应用,并提倡在该领域开展更多神经生理学和药理学研究。